| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Arthur S Kirsch is Director at LQDA, with reported holdings spanning 2 companies. Arthur S Kirsch's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.0M at current prices.
Our model assigns Arthur S Kirsch a middling insider score of 58/100, based on 5 past trades. Over a 12-month horizon, the one trade was profitable, with an average 12-month return of +15.6%.
Arthur S Kirsch's largest disclosed position is in LQDA as Director, worth about $2.0M.
Arthur S Kirsch has 14 Form 4 filings on record from March 2021 to July 2026, across 3 companies: Director at Evommune (EVMN), 2025–2026; Director at Atea Pharmaceuticals (AVIR), 2025–2026; Director at Liquidia (LQDA), 2021–2026.
The 17 reported transactions were 9 option or other derivative awards, 3 stock awards, 3 open-market sales and 2 open-market purchases.
Counted by filing, the open-market trades come to 2 purchases worth about $260K and 1 sale worth about $1.7M.
The largest open-market purchase was 10,000 shares of EVMN at an average $13.30 on July 7, 2026, about $133K.
The only open-market sale was 30,000 shares of LQDA at an average $57.71 on June 3, 2026, about $1.7M.